FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565932272> ?p ?o ?g. }

• W2565932272 abstract "Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PAAllogeneic hematopoietic stem cell transplantation (AHSCT) has been shown to provide longterm disease-free survival for otherwise fatal malignant or nonmalignant hematological disorders. Acute and chronic graft-versus-host disease (aGvHD and cGvHD) are a major complication following AHSCT and are associated with a substantial morbidity and mortality. Identification of patients (pts) likely to develop severe forms of GvHD could allow the selection of more aggressive therapeutic regimens for patients assessed to be at high risk.Serum samples and clinical data were available from 124 pts (age 18-70) who had received AHSCT. Five pts suffered no GvHD, 15 de novo cGvHD, 21 aGvHD but no cGvHD and 83 both aGvHD and cGvHD (overlap). Of pts with aGvHD 51% had grade I disease and of pts with cGvHD 53% had limited disease. Matrix assisted laser desorption/ionization (MALDI) mass spectra were acquired from the samples using the deep MALDI method, allowing a deep probing of the proteome. Spectra were preprocessed and spectral features defined. The integrated intensities of these features were combined with the clinical data using deep learning based machine learning to create classifiers able to stratify patients into groups depending on occurrence and severity of GvHD.Classifiers could be developed with significant power to predict occurrence and severity of GvHD. The area under the curves (AUCs) obtained for the clinical questions investigated and examples of the sensitivity and specificity achievable are summarized in the table.| | AUC | Sensitivity/Sensitivity |||| aGvHD ? | 0.74 | 63%/80% or 80%/65% || Grade II or severe aGvHD? | 0.65 | 60%/67% || cGvHD post aGvHD? | 0.75 | 63%/75% || severe vs mild cGvHD? | 0.68 | 67%/69% |It is possible to provide information on occurrence and severity of GvHD from mass spectral analysis of post-transplant serum samples. If validated, this panel of tests could provide additional information useful for clinicians choosing treatment regimens for pts following AHSCT.Citation Format: Heinrich Roder, Andreas-Claudius Hoffmann, Joanna Roder, Michael Koldehoff. A panel of mass spectrometry based serum protein tests for predicting graft-versus-host disease (GvHD) and its severity. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 599. doi:10.1158/1538-7445.AM2015-599" @default.
• W2565932272 created "2017-01-06" @default.
• W2565932272 creator A5006585307 @default.
• W2565932272 creator A5041775689 @default.
• W2565932272 creator A5062978338 @default.
• W2565932272 creator A5070454355 @default.
• W2565932272 date "2015-08-01" @default.
• W2565932272 modified "2023-09-27" @default.
• W2565932272 title "Abstract 599: A panel of mass spectrometry based serum protein tests for predicting graft-versus-host disease (GvHD) and its severity" @default.
• W2565932272 doi "https://doi.org/10.1158/1538-7445.am2015-599" @default.
• W2565932272 hasPublicationYear "2015" @default.
• W2565932272 type Work @default.
• W2565932272 sameAs 2565932272 @default.
• W2565932272 citedByCount "0" @default.
• W2565932272 crossrefType "proceedings-article" @default.
• W2565932272 hasAuthorship W2565932272A5006585307 @default.
• W2565932272 hasAuthorship W2565932272A5041775689 @default.
• W2565932272 hasAuthorship W2565932272A5062978338 @default.
• W2565932272 hasAuthorship W2565932272A5070454355 @default.
• W2565932272 hasConcept C126322002 @default.
• W2565932272 hasConcept C143998085 @default.
• W2565932272 hasConcept C203014093 @default.
• W2565932272 hasConcept C2777408962 @default.
• W2565932272 hasConcept C2779134260 @default.
• W2565932272 hasConcept C2779972918 @default.
• W2565932272 hasConcept C2911091166 @default.
• W2565932272 hasConcept C71924100 @default.
• W2565932272 hasConcept C90924648 @default.
• W2565932272 hasConceptScore W2565932272C126322002 @default.
• W2565932272 hasConceptScore W2565932272C143998085 @default.
• W2565932272 hasConceptScore W2565932272C203014093 @default.
• W2565932272 hasConceptScore W2565932272C2777408962 @default.
• W2565932272 hasConceptScore W2565932272C2779134260 @default.
• W2565932272 hasConceptScore W2565932272C2779972918 @default.
• W2565932272 hasConceptScore W2565932272C2911091166 @default.
• W2565932272 hasConceptScore W2565932272C71924100 @default.
• W2565932272 hasConceptScore W2565932272C90924648 @default.
• W2565932272 hasLocation W25659322721 @default.
• W2565932272 hasOpenAccess W2565932272 @default.
• W2565932272 hasPrimaryLocation W25659322721 @default.
• W2565932272 hasRelatedWork W2001039915 @default.
• W2565932272 hasRelatedWork W2015809954 @default.
• W2565932272 hasRelatedWork W2363489192 @default.
• W2565932272 hasRelatedWork W2388135870 @default.
• W2565932272 hasRelatedWork W2399280315 @default.
• W2565932272 hasRelatedWork W2539662592 @default.
• W2565932272 hasRelatedWork W2549401607 @default.
• W2565932272 hasRelatedWork W2556023833 @default.
• W2565932272 hasRelatedWork W2556913924 @default.
• W2565932272 hasRelatedWork W2561485808 @default.
• W2565932272 hasRelatedWork W2562442019 @default.
• W2565932272 hasRelatedWork W2587341234 @default.
• W2565932272 hasRelatedWork W2595721854 @default.
• W2565932272 hasRelatedWork W2614383378 @default.
• W2565932272 hasRelatedWork W2800364599 @default.
• W2565932272 hasRelatedWork W2979573275 @default.
• W2565932272 hasRelatedWork W3001327412 @default.
• W2565932272 hasRelatedWork W3002902233 @default.
• W2565932272 hasRelatedWork W3165100399 @default.
• W2565932272 hasRelatedWork W3199917877 @default.
• W2565932272 isParatext "false" @default.
• W2565932272 isRetracted "false" @default.
• W2565932272 magId "2565932272" @default.
• W2565932272 workType "article" @default.